Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xlife Sciences Ltd. ( (CH:XLS) ) has shared an announcement.
Xlife Sciences AG announced that DAZAmed, a liver-specific PET tracer developed in collaboration with x-nuclear diagnostics GmbH, inflamed pharma GmbH, and the University Hospital Jena, has won the Lothar Späth Award 2025. This recognition underscores the scientific and commercial potential of DAZAmed, marking a breakthrough in nuclear medicine for precise imaging of liver diseases. The award highlights Xlife Sciences’ capability to identify and commercialize innovative solutions, reinforcing its collaborative model between science, startups, and industry. The company plans to continue supporting the commercialization of DAZAmed, reflecting its success in accelerating development and bringing groundbreaking ideas to market.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss company that serves as an incubator and accelerator, focusing on the development and commercialization of promising research projects in the life sciences sector. The company aims to bridge the gap between research and healthcare markets by selecting projects in technology platforms, biotechnology, medical technology, and artificial intelligence, and advancing them to the next stage of development.
Average Trading Volume: 3,686
Technical Sentiment Signal: Buy
Current Market Cap: CHF141.3M
See more insights into XLS stock on TipRanks’ Stock Analysis page.